Valcyte (generic name: Valganciclovir Hydrochloride Tablets) is an antiviral medication, with valganciclovir hydrochloride as its main active ingredient. It is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). As a prodrug of ganciclovir, Valcyte is rapidly converted into ganciclovir in the body after oral administration to exert its therapeutic effect.

How to Use Valcyte

Recommended Dosage Regimen

Induction Therapy: For patients with active CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken twice daily with food, for a continuous period of 21 days.

Maintenance Therapy: After induction therapy, or for patients with inactive CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken once daily with food.

The medication should be swallowed whole. Do not crush, chew, or dissolve the tablets.

Important Administration Instructions

Valcyte must be taken with food to enhance its bioavailability (increasing the area under the curve (AUC) by approximately 30%).

It is recommended to take the medication at fixed times to ensure stable blood drug concentrations.

Since Valcyte is mainly excreted through the kidneys, dosage adjustments are required for patients with renal impairment.

Valcyte Dosage Adjustments

Dosage Adjustments for Patients with Renal Impairment

Creatinine Clearance (CrCl) ≥ 60 mL/min: Induction therapy – 900 mg twice daily; Maintenance therapy – 900 mg once daily.

CrCl 40–59 mL/min: Induction therapy – 450 mg twice daily; Maintenance therapy – 450 mg once daily.

CrCl 25–39 mL/min: Induction therapy – 450 mg once daily; Maintenance therapy – 450 mg once every two days.

CrCl 10–24 mL/min: Induction therapy – 450 mg once every two days; Maintenance therapy – 450 mg twice a week.

Hemodialysis Patients (CrCl < 10 mL/min): Valcyte tablets should not be used.

Dosage Adjustments Related to Adverse Reactions

Discontinue administration if the absolute neutrophil count is < 500 cells/μL, platelet count is < 25,000/μL, or hemoglobin level is < 8 g/dL.

Consider the use of hematopoietic growth factors in cases of grade 3–4 neutropenia.

If there is a significant increase in serum creatinine, re-evaluate renal function and adjust the dosage accordingly.

After improvement of adverse reactions, consideration may be given to restarting treatment at a lower dosage.

Precautions for Valcyte Use in Special Populations

Patients with Hepatic Impairment

Patients with mild to moderate hepatic impairment do not require dosage adjustments, but close monitoring for adverse reactions is necessary.

Caution is advised when using Valcyte in patients with severe hepatic impairment; it is recommended to start with a low dosage and conduct close monitoring.

Pregnant Women

Valcyte is classified as a Pregnancy Category C medication.

Animal studies have shown that ganciclovir has embryotoxic and teratogenic effects.

Women of childbearing age should use effective contraceptive measures during treatment and for at least 90 days after treatment completion.

Valcyte should be considered for use in pregnant women only if the potential benefits outweigh the potential risks.

Lactating Women

It is not yet clear whether Valcyte or ganciclovir is excreted into human milk.

Given the potential for serious adverse reactions in breastfed infants, breastfeeding should be discontinued during treatment.

Mothers infected with HIV should not breastfeed to avoid the risk of HIV transmission to the infant.